Obesity Therapeutics Case Study
Accelerating Entry into the Obesity Therapeutics Market Through Expert-Led Segmentation
A mid-sized pharma company aimed to enter the high-growth obesity therapeutics market dominated by GLP-1 therapies.
The Situation
A mid-sized pharma company aimed to enter the high-growth obesity therapeutics market dominated by GLP-1 therapies.
The Challenge
- Rapidly evolving competitive landscape
- Limited clarity on patient segmentation and treatment pathways
- Uncertainty in physician prescribing behavior
Our Approach
ApoInsights (Strategic Intelligence Network)
Engaged endocrinologists and metabolic disorder specialists globally to:
- Map real-world treatment pathways
- Identify underserved patient segments
- Validate switching behavior across therapies
ApoKynex (KOL Intelligence Platform)
- Translated expert inputs into structured patient segmentation models
- Integrated competitive intelligence and demand forecasting
- Delivered actionable go-to-market strategy frameworks
Key Insight
Significant opportunity existed in under-targeted patient segments beyond current high-focus cohorts.
Business Impact
- Identified $1.2B addressable opportunity
- Refined segmentation-led go-to-market strategy
- Accelerated launch readiness by 6 months
Strategic Outcome
From broad assumptions to precision-driven market entry.
.webp)